Rinofluimucil Spray Nasale


It is a N-acetylcisteine and Tuaminoheptane sulphate based compound nasal spray for treating rhinitis, sinusitis and nasal congestions.
Adults: Two deliveries per nostril, 3 to 4 times a day.

Children and adolescents over the age of 12: 1 delivery per nostril, 3 to 4 times a day.

Rinofluimucil in nasal spray is indicated for treating acute and sub-acute rhinitis, chronic rhinitis and muco-crusts, vasomotor rhinitis and sinusitis.
Rinofluimucil in nasal spray contains: active ingredient – N-acetylcisteine and Tuaminoheptane sulphate; excipients – Benzalkonium chloride, dithiotreitol, sodium edta, bibasic sodium phosphate, monobasic sodium phosphate, sodium hydroxide, alcohol, hypromellose, sorbitol 70% natural mint flavour, distilled water.
Rinofluimucil free the nasal cavity dissolving excess mucus; additionally it free inflamed nasal mucous membranes from congestion.
N-acetylcisteine exercises an intense mucolytic and fluidifying action on catarrh, depolymerising the protein complexes and nucleic acids that make it viscous; additionally it has an antioxidant action that inhibits the oxidant radicals and enhances the defence mechanism of the respiratory membranes. Tuaminoheptane sulphate frees nasal mucous membranes from congestion through an action of vasoconstriction without evident systemic effects.

The tuaminoheptane sulphate contained in Rinofluimucil is hardly absorbed at a systemic level at all through nasal mucous membranes; however the following interactions with other products may occur:

−    inhibitor of monoamine oxidase and reversible inhibitors of monoamine oxide, with possible increase in the risk of hypertensive crises;
−    Anti-hypertensive, adrenergic neurone blockers and beta blockers with possible blocking of hypotensive effects;
−    Cardiac glycosides, with possible increase of the risk of dysrhythmia;
−    Alkaloids of ergot with possible increase in risk of dysrhythmia;
−    Anti-Parkinson Drugs with possible increase in the risk of a cardiovascular toxicity;
−    Oxytocin with possible increase in the risk of hypertension.

Rinofluimucil is advised against in the following cases:

-    Hypersensitivity to the active ingredient or any one of the excipients
-    Narrow-angle glaucoma
-    Hyperthyroidism
-    During and in the two weeks subsequent to therapy with inhibitors of monoamine oxidase (IMAO).
-    Children younger than 12 years of age
-    Pheochromocytoma
-    During the use of other sympathomimetic drugs, including nasal decongestants.

-    Hypophysectomy or surgery with exposure of the dura mater.


The data relating to a limited number of women in pregnancy exposed to N-acetylcisteine have not indicated any adverse effect on the pregnancy itself or the health o foetus/new-born. There are moreover none in women in pregnancy exposed to tuaminoheptane or studies on animals with tuaminoheptane. In addition, there is no information available in respect of excretion of N-acetylcisteine and tuaminoheptane in mother’s milk; therefore Rinofluimucil is not recommended in pregnancy or during  breastfeeding and should be administered with caution at paediatric age.

In patients with cardiovascular illnesses, and especially the with hypertension, the use of nasal  decongestants must be put to the judgment from time to time of the doctor.

Administer with caution in parties affected by occlusive vascular disease, asthma, diabetes and in therapy with beta-blocker medication.

Use the product with caution for the risk of urinary retention in the elderly and in bearers of prostatic hypertrophy.

The use, especially if prolonged, of topic products may give rise to phenomena of sensitising; in this case it is necessary to interrupt treatment and, as the case may be, institute suitable therapy.

In the absence of a complete therapeutic response within a few days, consult a doctor; in any event, treatment must not be protracted for more than a week.

The action of the compound may be integrated, at the discretion of a doctor, with fitting antibacterial cover.

Tuaminoheptane sulphate may show positive to anti-doping.

Important: The preserving agent benzalkonium chloride may cause cutaneous reactions or bronchospasm. 




Nota: vi rendiamo attenti sul fatto che state per lasciare il sito Zambon Svizzera SA non ha alcuna influenza sui contenuti e sul concetto delle pagine linkate e declina quindi ogni responsabilità.